|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among RAS mediators, angiotensin II (AII) and angiotensin 1-7 (A1-7) have been mostly investigated in AF.
|
31375968 |
2020 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we investigated the effect of ubiquitin C-terminal hydrolase 1 (UCHL1), an important DUB, on the development of AF induced by angiotensin II (Ang II).
|
31700166 |
2020 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
The immunoproteasome is an inducible form of the proteasome and its catalytic subunit β5i (also named LMP7) is involved in angiotensin II-induced atrial fibrillation; however, its role in deoxycorticosterone-acetate (DOCA)-salt-induced cardiac remodeling remains unclear.
|
31629736 |
2019 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
NPR-C (Natriuretic Peptide Receptor-C) Modulates the Progression of Angiotensin II-Mediated Atrial Fibrillation and Atrial Remodeling in Mice.
|
30636477 |
2019 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Time Series Gene Expression Profiling and Temporal Regulatory Pathway Analysis of Angiotensin II Induced Atrial Fibrillation in Mice.
|
31191333 |
2019 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Angiotensin II (Ang-II)-induced fibroblast differentiation plays an important role in the development of atrial fibrosis and atrial fibrillation (AF).
|
31408621 |
2019 |
|
Atrial Fibrillation
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our previous investigation indicated that angiotensin II (Ang II) enhances the expression of Kv1.5, a promising target for the treatment of atrial fibrillation (AF), by activating reactive oxygen species (ROS)-dependent phosphorylation of Smad 2/3 (forming P-Smad 2/3) and ERK 1/2 (forming P-ERK 1/2).
|
31606204 |
2019 |
|
Atrial Fibrillation
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hypertensive patients carrying the control genotype of rs2074192 (CC, OR = 2.37, 95% CI: 1.28-4.39) were associated with CAS ≥50%, while those carrying a high-EH-risk genotype of rs4240157 (OR = 2.62, 95% CI: 1.24-5.54), rs4646155 (OR = 2.44, 95% CI: 1.16-5.10), or rs4830542 (CC+CT, OR = 2.20, 95% CI: 1.03-4.69) were associated with atrial fibrillation (AF), larger left atrial diameter, and higher levels of renin-angiotensin-aldosterone system (RAAS) activation (renin and angiotensin I/II).
|
30542083 |
2019 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study investigated the effects and mechanism of valsartan, an AngII receptor antagonist, on the susceptibility to AF with testosterone deficiency.
|
30016000 |
2018 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Angiotensin II (AngII) has been implicated in the initiation and maintenance of AF through changes in Ca<sup>2+</sup> handling and production of reactive oxygen species (ROS).
|
29625277 |
2018 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Novel Role for the Immunoproteasome Subunit PSMB10 in Angiotensin II-Induced Atrial Fibrillation in Mice.
|
29507100 |
2018 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Distinct patterns of atrial electrical and structural remodeling in angiotensin II mediated atrial fibrillation.
|
30273558 |
2018 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the effects of angiotensin-converting-enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) on thrombogenicity in AF remain incompletely elucidated.
|
28980280 |
2018 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Experimental studies suggest that angiotensin II-receptor blockers can influence atrial remodeling and may prevent atrial fibrillation (AF).
|
28886992 |
2018 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, the present study revealed that YY1-induced upregulation of lncRNA KCNQ1OT1 regulates angiotensin II-induced atrial fibrillation by regulating miR-384/CACNA1C axis.
|
30241939 |
2018 |
|
Atrial Fibrillation
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
After angiotensin-II (Ang-II) stimulation which mimicked atrial fibrosis progression, ALK4-deficient mice showed lower expression of ALK4 in atriums, reduced activation of atrial fibroblasts, blunted atrial enlargement and atrial fibrosis, and further reduced AF vulnerability upon right atrial electrophysiological studies as compared to wild-type littermates.
|
28639003 |
2017 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aims of this study include (i) pursuing data-mining experiments on the Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF-AFNET 2) trial dataset containing atrial fibrillation (AF) burden scores of patients with many clinical parameters and (ii) revealing possible correlations between the estimated risk factors of AF and other clinical findings or measurements provided in the dataset.
|
27733466 |
2017 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
H<sub>2</sub>S inhibits angiotensin II-induced atrial Kv1.5 upregulation by attenuating Nox4-mediated ROS generation during atrial fibrillation.
|
28011270 |
2017 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Renin-angiotensin system (RAS) inhibition via angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers may reduce the risk of developing atrial fibrillation (AF) in certain populations, but the evidence is conflicting.
|
27179719 |
2016 |
|
Atrial Fibrillation
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The present study investigated whether AGT variants correlate with the clinical outcome in patients with acquired AF after catheter ablation (CA).
|
26240116 |
2015 |
|
Atrial Fibrillation
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Patients with AF showed higher levels of angiotensin II (AngII) and TRIF expression and larger number of macrophages infiltration in left atria appendage than individuals with sinus rhythm (SR).
|
26056004 |
2015 |
|
Atrial Fibrillation
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The current meta-analysis suggested that the M235T polymorphism in the angiotensinogen gene might be related to the increased risk of AF in Asians.
|
25172907 |
2015 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genotyping of the angiotensinogen gene is helpful to determine which AF patients may benefit from treatment with an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker.
|
24732371 |
2014 |
|
Atrial Fibrillation
|
0.100 |
Biomarker
|
disease |
BEFREE |
Knock-in mice lacking critical oxidation sites in CaMKIIδ (MM-VV) and mice with myocardium-restricted transgenic overexpression of methionine sulfoxide reductase A, an enzyme that reduces oxidized CaMKII, were resistant to AF induction after angiotensin II infusion.
|
24030498 |
2013 |
|
Atrial Fibrillation
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ACE I/D polymorphism II genotype, angiotensinogen M235T polymorphism TT genotype and G allele and GG genotype of angiotensinogen G-6A polymorphism were still independently associated with AF when adjusted for left atrium, LVMI and presence of significant valvular pathology.
|
21436211 |
2011 |